These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33959132)

  • 1. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.
    Billon E; Chanez B; Rochigneux P; Albiges L; Vicier C; Pignot G; Walz J; Chretien AS; Gravis G; Olive D
    Front Immunol; 2021; 12():670827. PubMed ID: 33959132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
    Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
    Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
    Billon E; Dalban C; Oudard S; Chevreau C; Laguerre B; Barthélémy P; Borchiellini D; Geoffrois L; Negrier S; Joly F; Thiery-Vuillemin A; Gross-Goupil M; Rolland F; Priou F; Mahammedi H; Tantot F; Escudier B; Chabaud S; Albiges L; Gravis G
    Eur Urol Oncol; 2024 Aug; 7(4):742-750. PubMed ID: 37813745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
    Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
    Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
    Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
    Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
    Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
    Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
    Courcier J; Dalban C; Laguerre B; Ladoire S; Barthélémy P; Oudard S; Joly F; Gravis G; Chevreau C; Geoffrois L; Deluche É; Rolland F; Topart D; Culine S; Négrier S; Mahammedi H; Tantot F; Jamet A; Escudier B; Flippot R; Albigès L
    Eur Urol; 2021 Sep; 80(3):325-329. PubMed ID: 34103181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
    Carril-Ajuria L; Desnoyer A; Meylan M; Dalban C; Naigeon M; Cassard L; Vano Y; Rioux-Leclercq N; Chouaib S; Beuselinck B; Chabaud S; Barros-Monteiro J; Bougoüin A; Lacroix G; Colina-Moreno I; Tantot F; Boselli L; De Oliveira C; Fridman WH; Escudier B; Sautes-Fridman C; Albiges L; Chaput-Gras N
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
    Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
    Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
    Guilhem-Ducléon G; Dalban C; Negrier S; Gravis G; Laguerre B; Chevreau C; Oudard S; Barthelemy P; Ladoire S; Boughalem E; Borchiellini D; Linassier C; Nenan S; Flippot R; Albiges L; Goupil MG
    Clin Genitourin Cancer; 2023 Dec; 21(6):643-652. PubMed ID: 37635052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
    BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
    Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
    Rassy E; Dalban C; Colomba E; Derosa L; Alves Costa Silva C; Negrier S; Chevreau C; Gravis G; Oudard S; Laguerre B; Barthelemy P; Goupil MG; Geoffrois L; Rolland F; Thiery-Vuillemin A; Joly F; Ladoire S; Tantot F; Escudier B; Albiges L
    Clin Genitourin Cancer; 2022 Oct; 20(5):488-494. PubMed ID: 35977881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
    Mourey L; Rainho LT; Dalban C; Carril-Ajuria L; Negrier S; Chevreau C; Gravis G; Thibault C; Laguerre B; Barthelemy P; Borchiellini D; Gross-Goupil M; Geoffrois L; Rolland F; Thiery-Vuillemin A; Tantot F; Chaput N; Naigeon M; Teixeira M; Escudier B; Flippot R; Albiges L
    Eur J Cancer; 2024 Apr; 201():113589. PubMed ID: 38382153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.